Multi-omics analysis reveals the unique landscape of DLD in the breast cancer tumor microenvironment and its implications for immune-related prognosis

被引:2
|
作者
Xu, Lijun [1 ]
Yang, Lei [2 ,3 ,4 ]
Zhang, Dan [1 ]
Wu, Yunxi [1 ]
Shan, Jiali [1 ]
Zhu, Huixia [5 ]
Lian, Zhengyi [1 ]
He, Guying [1 ]
Wang, Chongyu [6 ]
Wang, Qingqing [1 ]
机构
[1] Nantong Univ, Med Sch Nantong Univ, Dept Gen Surg, Affiliated Hosp, Nantong, Peoples R China
[2] Nantong Univ, Dept Clin Biobank, Nantong, Peoples R China
[3] Nantong Univ, Inst Oncol, Affiliated Hosp, Nantong, Peoples R China
[4] Nantong Univ, Med Sch, Nantong, Peoples R China
[5] Nantong Univ, Med Coll, Dept Biochem, Nantong, Peoples R China
[6] Nantong Univ, Xinglin Coll, Dept Med, Nantong, Peoples R China
关键词
Cuproptosis; Breast cancer; Tumor immune microenvironment; Prognostic model; CELLS;
D O I
10.1016/j.csbj.2024.02.016
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Cuproptosis, i.e., copper-induced programmed cell death, has potential implications in cancer therapy. However, the impact of the cuproptosis-related gene (CRG) dihydrolipoyl dehydrogenase (DLD) on breast cancer (BC) prognosis remains underexplored. Methods: We employed real-time quantitative PCR and multiplexed immunostaining techniques to quantify DLD expression in both BC and the adjacent non-cancerous tissues. Immunofluorescence analysis was employed to assess the influence of DLD on immune cells and immunological checkpoints in the BC microenvironment. DLD knockdown experiments were conducted in BC cell lines MDA-MB-468 and SK-BR-3, with knockdown efficiency validated via western blot. Subsequently, we performed the cell counting kit-8 (CCK-8) assay, clone formation assay, Transwell migration assay, and invasion assay. To construct a prognostic model, we employed a Lasso-Cox regression analysis of immune-related genes associated with DLD. Additionally, we established a competing endogenous RNA network based on CRGs to evaluate potential regulatory pathways. Results: Compared to the adjacent tissues, BC tissues exhibited markedly elevated DLD expression levels. In vitro experiments demonstrated that DLD knockdown effectively inhibited BC cell migration, invasion, and proliferation. DLD exhibited positive correlations with CD68+ macrophages and PD-L1 in the tumor, as well as with macrophages and CD4+ T cells in the stroma. Tumor regions with high DLD expression were enriched in PD-L1 and macrophages, while stromal regions with high DLD expression contained CD4+ T cells and macrophages. The AUC values for 1-, 3-, and 5-year overall survival in TCGA-BRCA training set were 0.67, 0.66, and 0.66, respectively. A nomogram with a C-index of 0.715 indicated that risk score, tumor stage, and age could serve as independent prognostic factors for BC. Conclusion: Our findings underscore the significant predictive significance of DLD in BC and its influence on the tumor microenvironment. DLD represents a promising diagnostic and prognostic marker for BC, offering novel avenues for the identification of therapeutic targets and the enhancement of immunotherapy in BC.
引用
收藏
页码:1201 / 1213
页数:13
相关论文
共 50 条
  • [1] Integrative analysis of immune-related multi-omics profiles identifies distinct prognosis and tumor microenvironment patterns in osteosarcoma
    Shi, Deyao
    Mu, Shidai
    Pu, Feifei
    Liu, Jianxiang
    Zhong, Binlong
    Hu, Binwu
    Ni, Na
    Wang, Hao
    Luu, Hue H.
    Haydon, Rex C.
    Shen, Le
    Zhang, Zhicai
    He, Tong-Chuan
    Shao, Zengwu
    MOLECULAR ONCOLOGY, 2022, 16 (11) : 2174 - 2194
  • [2] Multi-omics analysis reveals the genetics and immune landscape of dexamethasone responsive genes in cancer microenvironment
    Shen, Yu
    Wu, Ying C.
    Gu, Lixiong
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (21)
  • [3] Integrative analyses of multi-omics data constructing tumor microenvironment and immune-related molecular prognosis model in human colorectal cancer
    Li, Yifei
    Li, Hexin
    Sun, Gaoyuan
    Xu, Siyuan
    Tang, Xiaokun
    Zhang, Lanxin
    Wan, Li
    Zhang, Lili
    Tang, Min
    HELIYON, 2024, 10 (12)
  • [4] Tumor Microenvironment Subtypes and Immune-Related Signatures for the Prognosis of Breast Cancer
    Han, Yiqun
    Wang, Jiayu
    Xu, Binghe
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [5] A multi-omics analysis reveals CLSPN is associated with prognosis, immune microenvironment and drug resistance in cancers
    Chen, Yihong
    Wen, Haicheng
    Li, Yin
    Han, Ying
    Tan, Jun
    Guo, Cao
    Cai, Changjing
    Liu, Ping
    Peng, Yinghui
    Liu, Yihan
    Wang, Xinwen
    Zeng, Shan
    Feng, Ziyang
    Shen, Hong
    BIOLOGICAL PROCEDURES ONLINE, 2023, 25 (01)
  • [6] A multi-omics analysis reveals CLSPN is associated with prognosis, immune microenvironment and drug resistance in cancers
    Yihong Chen
    Haicheng Wen
    Yin Li
    Ying Han
    Jun Tan
    Cao Guo
    Changjing Cai
    Ping Liu
    Yinghui Peng
    Yihan Liu
    Xinwen Wang
    Shan Zeng
    Ziyang Feng
    Hong Shen
    Biological Procedures Online, 25
  • [7] Multi-omics analysis of pyroptosis-related genes for prognosis and immune landscape in head and neck cancer
    Zheng, Shikang
    Liu, Qinghua
    Wang, Cheng
    Zhang, Rongqi
    Peng, Xin
    Fan, Junda
    Xu, Haiming
    Pan, Xiazhi
    Chen, Nanxiang
    Liu, Mingbo
    Zhao, Kai
    CLINICAL AND TRANSLATIONAL MEDICINE, 2024, 14 (12):
  • [8] Multi-Omics Data Analyses Construct a Six Immune-Related Genes Prognostic Model for Cervical Cancer in Tumor Microenvironment
    Xu, Fangfang
    Shen, Jiacheng
    Xu, Shaohua
    FRONTIERS IN GENETICS, 2021, 12
  • [9] Comprehensive Landscape of Ovarian Cancer Immune Microenvironment Based on Integrated Multi-Omics Analysis
    Shen, Jiacheng
    Liu, Tingwei
    Bei, Qiaoli
    Xu, Shaohua
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [10] Multi-omics approach reveals the impact of prognosis model-related genes on the tumor microenvironment in medulloblastoma
    Han, Dongming
    Chen, Xuan
    Jin, Xin
    Li, Jiankang
    Wang, Dongyang
    Wang, Ziwei
    FRONTIERS IN ONCOLOGY, 2025, 15